Published Studies Related to Cogentin (Benztropine)
Paralytic ileus requiring hospitalization secondary to high-dose antipsychotic polypharmacy and benztropine. [2011.03]
Ileus can result from the combined activity of antipsychotic and anticholinergic medications... Providers should minimize antipsychotic and concurrent anticholinergic medications, consider prophylactic bowel regimens and monitor for constipation.
N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. [2011.02]
Previous studies suggested that differences between the behavioral effects of cocaine and analogs of benztropine were related to the relatively slow onset of action of the latter compounds. Several N-substituted benztropine analogs with a relatively fast onset of effects were studied to assess whether a fast onset of effects would render the effects more similar to those of cocaine.
Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. [2009.05]
Benztropine (BZT) analogs inhibit dopamine uptake but are less effective than cocaine in producing behavioral effects predicting abuse liability. The present study compared reinforcing effects of intravenous BZT analogs with those of standard monoamine uptake inhibitors and the effects of their oral pretreatment on cocaine self-administration...
The novel N-substituted benztropine analog GA2-50 possesses pharmacokinetic and pharmacodynamic profiles favorable for a candidate substitute medication for cocaine abuse. [2008.12]
GA2-50 is a novel N-substituted benztropine analog with improved potency and selectivity for the dopamine transporter. The pharmacokinetic and pharmacodynamic properties of GA2-50 were characterized as a part of its preclinical evaluation as a substitute medication for cocaine abuse...
Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. [2008.06.05]
Benztropine (BZ) is a potent muscarinic receptor antagonist that has been used for the treatment of Parkinson disease. However, the oral administration of BZ is often limited because of its many dose-related side effects...
Clinical Trials Related to Cogentin (Benztropine)
Evaluation of Benztropine for Cocaine Craving - 2 [Completed]
The purpose of this study is to compare the efficacy of benztropine (or DA reuptake
inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.
Effect of Antidepressants on Back Pain [Completed]
The purpose of this study is to determine whether different types of antidepressant
medicines relieve back pain that has lasted at least six months on a daily basis. Study
participants will be assigned to treatment with either a antidepressant acting on the
serotonin system in the brain (fluoxetine), one acting on the noradrenaline system
(desipramine, or to a control medication not expected to relieve pain (benztropine). Each
participant will be seen at least nine times during their 12 weeks on medication. This is a
phase 2/3, outpatient study.
Anticholinergic Burden in Schizophrenia [Terminated]
Anticholinergic antiparkinsonian agents often cause side-effects including cognitive
impairment, dry mouth, and constipation while they diminish antipsychotic-induced
parkinsonian symptoms. The introduction of second generation antipsychotics (SGA) brought
fewer neurological side effects. However, anticholinergic coprescription rates are still as
high as 12-65% in patients on SGA that are much higher than the incidence of EPS reported in
clinical trials (3-20%). This apparently discrepancy is likely explained, in part, by the
established tradition of routine use of this medications. Older patients are particularly
sensitive to anticholinergic side-effects due to age-related changes in pharmacokinetics and
pharmacodynamics. In this study, we will examine the safety and benefits of reducing the
dose of a frequently prescribed anticholinergics, benztropine, on cognitive function,
extrapyramidal symptoms, and psychotic symptoms in older subjects with a primary psychotic
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia [Completed]
This study will compare the safety and effectiveness of three different antipsychotic
medications, as well as the use of other medications to limit treatment side effects, in
adults with schizophrenia.
A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room [Completed]
In the Psychiatric Emergency Room, agitated patients are treated routinely with an I. M.
Haloperidol "cocktail" (Haloperidol 5 mg, Lorazepam 2 mg, Cogentin 2 mg), which has proved
to be an effective treatment. However, since it is an intramuscular injection, it is more
complicated and perhaps less acceptable to patients as well as more likely to cause EPS
(extrapyramidal symptoms). Of late in our emergency room, we started using high dose
Quetiapine 300 mg PO to replace the "cocktail" for treating agitation. It has shown
This study is designed to compare the efficacy and safety of Quetiapine with the routine
"cocktail for treatment of agitation.
The primary purpose of this study is to determine the efficacy and safety of Quetiapine by
using high dose Quetiapine (300 mg) PO to treat agitated patients in the psychiatric
The secondary purpose is to test the immediate effect on agitation caused by illicit drug
abuse or the alcohol abuse.
Reports of Suspected Cogentin (Benztropine) Side Effects
Muscle Spasms (11),
Gait Disturbance (11),
Tardive Dyskinesia (11),
Movement Disorder (10),
Muscle Tightness (10),
Abnormal Behaviour (10),
Weight Decreased (9),
Drug Ineffective (9), more >>